Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020

It is to be feared that the great vulnerability of patients with cardiovascular diseases to the coronavirus disease 2019 (COVID-19) pandemic will further heighten the already enormous burden of morbidity and mortality of heart failure. Many of the clinical trials published in 2020 show the favorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Birner, Christoph, Laufs, Ulrich, Frey, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Schwerpunkt
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903396/
http://dx.doi.org/10.1007/s12181-021-00446-z
_version_ 1783654728684535808
author Birner, Christoph
Laufs, Ulrich
Frey, Norbert
author_facet Birner, Christoph
Laufs, Ulrich
Frey, Norbert
author_sort Birner, Christoph
collection PubMed
description It is to be feared that the great vulnerability of patients with cardiovascular diseases to the coronavirus disease 2019 (COVID-19) pandemic will further heighten the already enormous burden of morbidity and mortality of heart failure. Many of the clinical trials published in 2020 show the favorable effects of innovative treatment principles. For the treatment of systolic heart insufficiency (heart failure with reduced ejection fraction, HFrEF) sodium-glucose cotransporter 2 (SGLT2) inhibitors and sacubitril/valsartan are prioritized.
format Online
Article
Text
id pubmed-7903396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-79033962021-02-24 Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020 Birner, Christoph Laufs, Ulrich Frey, Norbert Kardiologe Schwerpunkt It is to be feared that the great vulnerability of patients with cardiovascular diseases to the coronavirus disease 2019 (COVID-19) pandemic will further heighten the already enormous burden of morbidity and mortality of heart failure. Many of the clinical trials published in 2020 show the favorable effects of innovative treatment principles. For the treatment of systolic heart insufficiency (heart failure with reduced ejection fraction, HFrEF) sodium-glucose cotransporter 2 (SGLT2) inhibitors and sacubitril/valsartan are prioritized. Springer Medizin 2021-02-24 2021 /pmc/articles/PMC7903396/ http://dx.doi.org/10.1007/s12181-021-00446-z Text en © Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Schwerpunkt
Birner, Christoph
Laufs, Ulrich
Frey, Norbert
Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title_full Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title_fullStr Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title_full_unstemmed Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title_short Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
title_sort neue therapiekonzepte für die herzinsuffizienz: studien-highlights 2020
topic Schwerpunkt
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903396/
http://dx.doi.org/10.1007/s12181-021-00446-z
work_keys_str_mv AT birnerchristoph neuetherapiekonzeptefurdieherzinsuffizienzstudienhighlights2020
AT laufsulrich neuetherapiekonzeptefurdieherzinsuffizienzstudienhighlights2020
AT freynorbert neuetherapiekonzeptefurdieherzinsuffizienzstudienhighlights2020

Ejemplares similares